R&D â key to the future - Boehringer-Ingelheim
R&D â key to the future - Boehringer-Ingelheim
R&D â key to the future - Boehringer-Ingelheim
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
2<br />
4<br />
8<br />
12<br />
16<br />
20<br />
22<br />
24<br />
25<br />
26<br />
28<br />
29<br />
30<br />
32<br />
38<br />
40<br />
42<br />
44<br />
45<br />
46<br />
48<br />
52<br />
53<br />
Contents<br />
Introduction<br />
Building and improving R&D strengths<br />
The scope of our clinical research<br />
R&D Germany – Discovery concentrated at Biberach<br />
R&D USA – Key player in immunology and inflammation<br />
R&D Canada – Center for virology research<br />
R&D Austria – Drug discovery for cancer medicines<br />
R&D Japan – Our Asian research arm<br />
Virtual Research Institute of Aging<br />
IMP – The life science think-tank<br />
Constructive cooperation with Nature<br />
R&D Licensing<br />
Targeting new terri<strong>to</strong>ry – Genomics, proteomics, bioinformatics<br />
Genome research – The challenging road ahead<br />
Highlights from <strong>the</strong> past<br />
e-R&D – Mastering <strong>the</strong> data flood<br />
R&D – The IT Strategy Project<br />
Activities in drug delivery<br />
Managing <strong>the</strong> interface between R&D and Operations<br />
B.I.F. – Building trust in <strong>the</strong> scientific community<br />
Ethics in biotechnology<br />
The <strong>Boehringer</strong> <strong>Ingelheim</strong> world of R&D<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s R&D Centers<br />
1
Change language